| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
Biochemical reagent; natural alkaloid
|
|---|---|
| ln Vitro |
Sophoridine (0-500 μM; 48 hours) has an IC50 value of roughly 20 μM to 200 μM, which significantly inhibits the growth of human pancreatic cancer, gastric cancer, liver cancer, colon cancer, gallbladder cancer, and prostate cancer cells [1]. Sophoridine (0-20 μM; 48 hours) increased the S-phase cell population in Miapaca-2 cells from 26.23% (control) to 38.67% and in PANC-1 cells from 29.56% (control). control) increased to 39.16%, approximately 1.5 times and 1.3 times respectively [1]. In contrast, sophoridin (0–20 μM; 48 hours) significantly lowers bcl-2 and bcl–xl levels while significantly raising the Bax/Bcl-2 ratio [1]. It also significantly raises bad and bax levels.
|
| ln Vivo |
Sophoridine (ip; 20 or 40 mg/kg; 21 days) suppresses the growth of pancreatic tumors that have been xenografted [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: Normal cells: IOSE144, HL-7702 and LO2, BEAS-2B, GES-1, HEK 293 T, HPDE, FHC, human cancer cells: PANC-1, Mapaca-1, hepG2, SGC-7901, CBC-SD, SGC-996, PC-3, MKN-45, MGC-803, Hela and HCT116 cell Tested Concentrations: 0, 3.9, 7.8, 15.5, 31, 62.5, 125, 250, 500 μM Incubation Duration: 48 hrs (hours) Experimental Results: demonstrated the most effective cytotoxicity against cancer cells. Cell cycle analysis [1] Cell Types: PANC-1 cells; Miapca-2 cells Tested Concentrations: 20 μM Incubation Duration: 48 hrs (hours) Experimental Results: Resulting in S phase population accumulation. Western Blot Analysis [1] Cell Types: PANC-1 cells; Miapca-2 cells Tested Concentrations: 20 μM Incubation Duration: 48 hrs (hours) Experimental Results: Induction of activation of intrinsic apoptotic pathway. |
| Animal Protocol |
Animal/Disease Models: BALB/c homozygous (nu/nu) nude mice [1]
Doses: 20 or 40 mg/kg Route of Administration: intraperitoneal (ip) injection; 20 or 40 mg/kg; 21-day Experimental Results: Xenograft pancreatic tumor mass reduction. |
| Toxicity/Toxicokinetics |
mouse LD50 oral 243 mg/kg Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal., 27(201), 1992
mouse LD50 intravenous 46800 ug/kg Yaowu Fenxi Zazhi. Journal of Pharmaceutical Analysis., 6(96), 1986 mouse LD50 intraperitoneal 64300 ug/kg Zhongguo Yaoli Xuebao. Acta Pharmacologica Sinica. Chinese Journal of Pharmacology., 8(153), 1987 [PMID:2959003] |
| References | |
| Additional Infomation |
Sophoridine has been reported in Euchresta japonica, Leontice leontopetalum, and other organisms with data available.
Tetracyclic bis-quinolizidine alkaloids found in the family LEGUMINOSAE, mainly in the genus SOPHORA. Background: Pancreatic cancer is generally acknowledged as the most common primary malignant tumor, and it is known to be resistant to conventional chemotherapy. Novel, selective antitumor agents are pressingly needed. Methods: CCK-8 and colony formation assay were used to investigate the cell growth. Flow cytometry analysis was used to evaluate the cell cycle and cell apoptosis. The peroxide-sensitive fluorescent probe DCFH-DA was used to measure the intracellular ROS levels. Western blot assay was used to detect the levels of cell cycle and apoptosis related proteins. Xenografts in nude mice were used to evaluate the effect of Sophoridine on pancreatic cancer cell in vivo. Results: Sophoridine killed cancer cells but had low cytotoxicity to normal cells. Pancreatic cancer cells were particularly sensitive. Sophoridine inhibited the proliferation of pancreatic cancer cells and induced cell cycle arrest at S phase and mitochondrial-related apoptosis. Moreover, Sophoridine induced a sustained activation of the phosphorylation of ERK and JNK. In addition, Sophoridine provoked the generation of reactive oxygen species (ROS) in pancreatic cancer cells. Finally, in vivo, Sophoridine suppressed tumor growth in mouse xenograft models. Conclusion: These findings suggest Sophoridine is promising to be a novel, potent and selective antitumor drug candidate for pancreatic cancer.[1] |
| Molecular Formula |
C15H24N2O
|
|---|---|
| Molecular Weight |
248.3639
|
| Exact Mass |
248.188
|
| Elemental Analysis |
C, 72.54; H, 9.74; N, 11.28; O, 6.44
|
| CAS # |
6882-68-4
|
| Related CAS # |
d-Sophoridine;83148-91-8; 145572-44-7 (hydrate)
|
| PubChem CID |
165549
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
396.7±31.0 °C at 760 mmHg
|
| Melting Point |
109 °C
|
| Flash Point |
172.7±17.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
1.44
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
356
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O=C1C([H])([H])C([H])([H])C([H])([H])[C@]2([H])[C@@]3([H])C([H])([H])C([H])([H])C([H])([H])N4C([H])([H])C([H])([H])C([H])([H])[C@]([H])(C([H])([H])N21)[C@]43[H]
|
| Synonyms |
Sophoridine; 6882-68-4; Sophoridin; 5-Epidihydrosophocarpine; (5-beta)-Matridin-15-one; (-)Sophoridine; W5S1M800J7; 6882-68-4 (free);
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~201.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (8.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (8.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.17 mg/mL (8.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0264 mL | 20.1321 mL | 40.2641 mL | |
| 5 mM | 0.8053 mL | 4.0264 mL | 8.0528 mL | |
| 10 mM | 0.4026 mL | 2.0132 mL | 4.0264 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
